What is Iovance Biotherapeutics, Inc.'s G&A?

Iovance Biotherapeutics, Inc. (IOVA) reported G&A of $38.95M in Q1 2026.

How has Iovance Biotherapeutics, Inc.'s G&A changed year-over-year?

Iovance Biotherapeutics, Inc.'s G&A decreased by 11.1% year-over-year, from $43.8M to $38.95M.

What is the long-term trend for Iovance Biotherapeutics, Inc.'s G&A?

Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s G&A has grown at a 16.2% compound annual growth rate (CAGR), from $83.66M to $152.45M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Iovance Biotherapeutics, Inc. IOVA G&A

G&A at other companies

ImmunomeIMNM

$12.95M+21.1%

Immunovant, Inc.IMVT

$17.27M-14.4%

Protagonist TherapeuticsPTGX

$13.28M+13.1%

Summit TherapeuticsSMMT

$62.59M+302%

Vera TherapeuticsVERA

$39.12M+146%

Enliven TherapeuticsELVN

$7.14M+5.0%

Segments

By segment

See full

Single Reportable$18.7M-5.8%

Other financials

Income statement

See full

Revenue$71.4M+44.8%

Gross profit$28.9M+338%

Operating income-$81.0M+33.1%

Net income-$79.0M+32.0%

EPS (diluted)-$0.19+47.2%

Balance sheet

See full

Cash & equivalents$196.5M+14.5%

Total debt$46.8M-11.3%

Total equity$721.8M-6.0%

Total assets$925.7M-4.2%

Cash flow

See full

Operating cash flow-$72.1M+30.5%

CapEx$6.6M+6.4%

Free cash flow-$78.7M+28.4%

Valuation

See full

Market cap$1.98B+32.4%

Enterprise value$1.83B+33.2%

P/S6.9×-0.1×

Profitability

See full

Gross margin36.7%+4.1pp

Operating margin-127.2%-31.0pp

Net margin-123.9%-28.4pp

FCF margin-106.8%-27.5pp

Returns & leverage

See full

Return on equity-47.5%-3.7pp

Debt / equity0.1×0.0×

Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s G&A?: Iovance Biotherapeutics, Inc. (IOVA) reported G&A of $38.95M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s G&A changed year-over-year?: Iovance Biotherapeutics, Inc.'s G&A decreased by 11.1% year-over-year, from $43.8M to $38.95M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s G&A?: Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s G&A has grown at a 16.2% compound annual growth rate (CAGR), from $83.66M to $152.45M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.